Table 4.
Treatment-emergent adverse events
| All participants (n = 8) | |
|---|---|
| TEAE summary, n (%) | |
| Any TEAE | 6 (75) |
| Any serious TEAE | 0 |
| Any TEAE leading to discontinuation | 0 |
| Any TEAE resulting in death | 0 |
| All TEAEs by MedDRA preferred term, n (%) | |
| Headachea | 2 (25) |
| Arthropod sting | 1 (13) |
| Blepharospasm | 1 (13) |
| Dermatitis contact | 1 (13) |
| Dizzinessa | 1 (13) |
| Frequent bowel movements | 1 (13) |
| Gastritis | 1 (13) |
| Myalgia | 1 (13) |
| Nasopharyngitis | 1 (13) |
| Pyrexia | 1 (13) |
| Vomiting | 1 (13) |
Abbreviations: MedDRA, Medical Dictionary for Regulatory Activities; TEAE, treatment-emergent adverse event.
Mild headache and mild dizziness (each in 1 participant) were judged by the investigator as “possibly” related to study drug.